№ files_lp_3_process_9_45185
File format: docx
Character count: 5006
File size: 81 KB
Year:
2023
Region / City:
Texas
Theme:
Historic Preservation
Document Type:
Application Form
Organization:
Texas Historical Commission
Author:
Texas Historical Commission
Target Audience:
Cemetery Administrators, Historical Markers Sponsors
Approval Date:
2023-01-01
Modification Date:
2023-01-01
Period of Validity:
Until marker approval
Date of Submission:
2023-01-01
Marker Title:
Historic Texas Cemetery Marker
Marker Type:
HTC Medallion, Name & Date Plaque
Shipping Address:
Required business street address
Approval Process:
Completed HTC designation required
Payment Information:
Non-refundable application fee of $100, with a 45-day payment deadline
Marker Fees:
Subject to change due to material costs
Description:
Application form for requesting a Historic Texas Cemetery marker with Medallion and Name & Date Plaque, requiring prior HTC designation approval and payment process.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2022
Region / City:
Wilmington
Topic:
Historic Preservation
Document Type:
Application Instructions
Organization / Institution:
Historic Wilmington Foundation
Author:
Historic Wilmington Foundation
Target Audience:
Property Owners
Effective Period:
Ongoing
Approval Date:
April 2022
Amendment Date:
N/A
Drug name:
Apremilast
Brand name:
Otezla
Dosage form:
Tablet
Strength:
30 mg
Pack composition:
4 tablets of 10 mg, 4 tablets of 20 mg, 19 tablets of 30 mg
Sponsor:
Amgen Australia Pty Ltd
Regulatory status:
TGA registered
TGA registration date:
19 March 2015
Indication:
Severe plaque psoriasis
Previous indication:
Psoriatic arthritis and moderate to severe plaque psoriasis
Application type:
Minor resubmission
Requested listing:
PBS General Schedule, Authority Required (STREAMLINED)
Comparator:
Cyclosporin
Clinical population:
Patients with severe plaque psoriasis intolerant of or contraindicated to methotrexate
Primary outcome:
PASI-75 at 16 weeks
Clinical claim:
Non-inferior comparative efficacy and safety versus cyclosporin
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission history period:
2015–2018
Geographic scope:
Australia
Source type:
Public summary document excerpt
Note:
Year
Year:
2024
Region / City:
Australia
Topic:
Psoriasis Treatment
Document Type:
Patient Handout
Organization:
Victorian Government, Department of Health
Author:
Not specified
Target Audience:
Patients with mild plaque psoriasis
Period of validity:
Not specified
Approval Date:
March 2024
Amendment Date:
Not specified
Cost Information:
Free consultation; medicine costs vary based on Medicare and PBS status
Eligibility:
Adults aged 18 or older with mild plaque psoriasis
Additional Support:
Websites provided for more information
Complaint Process:
Information on complaints available at www.health.vic.gov.au/feedback-and-complaints
Safety Net Information:
Medications not included in PBS Safety Net
Consultation Details:
Private consultation with a pharmacist
Prescription Information:
Medicines under PBS or full price for non-listed items
International Students:
Eligible based on specific countries
Consent Process:
Provided during consultation
Health Advice:
Self-care and lifestyle tips included
Expected Outcome:
Symptoms should improve within 2-4 weeks
What to do if symptoms worsen:
Visit a doctor if no improvement or worsening of condition
Contact:
[email protected]
Year:
2014
Region / city:
Australia
Topic:
Pharmaceutical benefits scheme, biological disease-modifying anti-rheumatic drugs (bDMARDs), chronic plaque psoriasis
Document Type:
Research report
Organization / institution:
Drug utilisation sub-committee (DUSC)
Author:
Not specified
Target Audience:
Healthcare professionals, policymakers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2026
Region / city:
Not specified
Topic:
Guselkumab treatment for pediatric plaque psoriasis
Document type:
Research study
Institution:
Not specified
Author:
Vimal H. Prajapati, Marieke M.B. Seyger, Dagmar Wilsmann-Theis, Erzsebet Szakos, Andrzej Kaszuba, Bart van Hartingsveldt, Meg Jett, Gigi Jiang, Shu Li, Vikash Sinha, Herta Crauwels, Cynthia M.C. DeKlotz, Amy S. Paller
Target audience:
Healthcare professionals, dermatologists
Study period:
Not specified
Date of approval:
Not specified
Date of revisions:
Not specified
Description:
Phase 3, randomized, placebo-controlled study of Guselkumab for pediatric patients with moderate-to-severe plaque psoriasis.
Year:
2020
Region / City:
International
Topic:
Biochemical and Molecular Markers, Plant Varieties
Document Type:
Draft
Organization / Institution:
International Union for the Protection of New Varieties of Plants (UPOV)
Author:
UPOV Office
Target Audience:
Technical Committee, Administrative and Legal Committee, and Council of UPOV
Effective Period:
2020
Approval Date:
August 10, 2020
Date of Changes:
Not specified
Context:
Guidance document outlining methods for using biochemical and molecular markers to assess distinctness, uniformity, and stability of new plant varieties for UPOV compliance.
Year:
2021
Program:
Recorded Texas Historic Landmark (RTHL)
Document type:
Official application form and coversheet
Issuing body:
Texas Historical Commission
Purpose:
Request for approval of an Official Texas Historical Marker
Applicable properties:
Buildings and structures at least 50 years old
Geographic scope:
Texas, United States
Application period validity:
March 1 – May 15, 2021
Application fee:
$100
Designation criteria:
Age, historical significance, architectural significance, integrity, good state of repair
Legal reference:
Texas Government Code Section 442.006(f)
Submission email:
[email protected]
Year:
2023
Region / City:
Washington State
Theme:
Raised pavement markers, procurement process
Document Type:
Contract FAQ
Organization / Institution:
Washington State Department of Enterprise Services
Author:
Washington State Department of Enterprise Services
Target Audience:
Washington State agencies, institutions of higher education, political subdivisions, and contractors
Period of Validity:
Ongoing until contract replacement
Approval Date:
N/A
Amendment Date:
N/A
Contractor Performance Metrics:
Order confirmation, lead time, invoice corrections, delivery notification, insurance endorsements, vendor management fee, contract sales reports
Pricing Model:
Unit pricing per line item
Federal Funding Impact:
Restrictions on reserved awards
Environmental Certifications:
N/A
Vendor Management:
Required timely payments and reporting
Year:
2025
Region / City:
Central Bureau of Materials
Topic:
Pavement Marking
Document Type:
Special Provision
Organ / Institution:
Department of Transportation
Author:
Jack A. Elston
Target Audience:
Engineers, Contractors
Effective Date:
November 1, 2025
Date of Approval:
July 25, 2025
Date of Changes:
November 7, 2025
Year:
2020
Region / City:
Texas
Topic:
Historical markers, Age and Accessibility requirements
Document type:
Form
Organization:
Texas Historical Commission
Author:
Texas Historical Commission
Target audience:
Individuals submitting historical marker topics
Validity period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Year:
Not specified
Region / City:
Not specified
Topic:
Immunohistochemistry markers analysis
Document type:
Research table
Organization / Institution:
Not specified
Author:
Not specified
Target audience:
Researchers in histopathology, immunology, or related fields
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Date:
January 17, 2021
Type of document:
Cover letter
Purpose:
Submission of an original research article for publication
Journal:
Functional Foods in Health and Disease
Author:
Johnny Percy Ambulay Briceño, MSc
Affiliation:
Micronutrients Laboratory, Laboratories for Research and Development, Universidad Peruana Cayetano Heredia
Institution address:
Av. Honorio Delgado 430, San Martin de Porres, Lima 31, Perú
Subject of manuscript:
Effects of oil emulsion from Plukenetia huayllabambana on nitric oxide, leptin, antioxidant and inflammation markers in obese rats
Funding statement:
Article publication fee of $895.00 US dollars to be paid via PayPal invoice
Publication status:
Not published and not under consideration elsewhere
Recommended peer reviewers:
Salma M. Eraky; Solomon E. Owumi; Zatollah Asemi; Ghadha Ibrahim Fouad; Jing Hui
Co-authors:
Percy A. Rojas; Olga S. Timoteo; Teresa V. Barreto; Zayra N. Vila; M. B. De los Santos; Maria Eguiluz; Ana Colarossi
Year:
2010
Region / city:
Not specified
Subject:
Polymorphism of SSR markers
Document type:
Research data
Author:
Wang et al.
Target audience:
Researchers in molecular genetics
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Reference:
Wang et al., 2010; Wang et al., 2018; Mei et al., 2014; Ulloa et al., 2013; Lopez-Lavalle et al., 2012; Abdelraheem et al., 2022
Contextual description:
This is a dataset documenting polymorphic SSR markers for FOV races and their respective polymorphism information content (PIC) and heterozygosity (He) values, used for genetic analysis in cotton.
Year:
2025
Section Number:
00855
Document Code:
SP00855
Region:
Oregon
Subject:
Pavement markers and payment provisions
Document Type:
Special provisions specification section
Organization:
Oregon Department of Transportation (ODOT)
Related Standard:
Standard Specifications Section 00855
Effective Bidding Date:
10-01-2025
Last Updated:
06-26-2025
Work Category:
Roadway pavement marking infrastructure
Payment Basis:
Contract unit price per unit of measurement
Payment Items:
Mono-Directional Type I Markers; Mono-Directional Type IAR Markers; Bi-Directional Type I Markers; Bi-Directional Type IAR Markers; Type II Markers; Recessed Type IAR Markers
Measurement Unit:
Each
Included Costs:
Materials, equipment, labor, and incidentals for installation
Excluded Separate Payment:
Pavement grooves, pavement preparation, adhesive, clean-up
Year:
2021
Region / city:
N/A
Topic:
Hepatitis B treatment
Document type:
Research study
Organization:
N/A
Author:
N/A
Target audience:
Healthcare professionals
Period of validity:
N/A
Approval date:
N/A
Modification date:
N/A
Year:
2023
Region / city:
Karaj, Iran
Subject:
Obesity, probiotics, metabolic health
Document type:
Clinical trial report
Organization / institution:
Tabriz University of Medical Sciences, Alborz University of Medical Sciences, Islamic Azad University
Author:
Faezeh Amani, Jamileh Ghalami, Leila Roozbeh-Nasiraie, Behzad Alaeddini, Vahidah Ebrahimzadeh Attari
Target audience:
Researchers, healthcare professionals, medical scientists
Period of validity:
2023
Approval date:
2023-06-08
Date of changes:
None
Keywords:
Probiotics, Lactobacillus, Omentin-1, Obesity, Lipid profile, Glycemic control
Year:
2026
Region / City:
South Dakota
Topic:
Historical Preservation
Document Type:
Application Criteria
Organization:
South Dakota State Historic Preservation Office
Author:
South Dakota State Historic Preservation Office
Target Audience:
Individuals and organizations interested in applying for a historical marker
Effective Period:
Until December 31st, 2026
Approval Date:
February 2026
Modification Date:
February 2026
Year:
2025
Location:
Diwaniyah, Iraq
Study Type:
Cross-sectional study
Patient Group:
Transfusion-dependent β-thalassemia major patients
Sample Size:
50
Age Range:
3–23 years
Gender Distribution:
54% male
Primary Measurements:
Serum vitamin D3, liver enzymes (ALT, AST, ALP), total bilirubin, lipids, minerals
Methodology:
Chemiluminescence immunoassay (CLIA), automated biochemical analyzer
Ethical Approval:
Diwaniyah Health Directorate Institutional Review Board, Approval No. 4696-12-3-2025
Period of Data Collection:
April 20, 2025 – July 20, 2025
Keywords:
β-Thalassemia Major, Vitamin D3, Liver Function, Iron Overload, Iraq
Year:
2026
Region / City:
Not specified
Subject:
Bone mineral density and bone turnover markers
Document Type:
Supplementary figures from clinical study
Institution:
Labcorp referenced for laboratory values
Author:
Not specified
Study Population:
Pre- and post-menopausal women, men
Markers Measured:
BMD Z-scores, CTx, P1NP
Measured Sites:
Lumbar spine, total hip, femoral neck, distal radius
Data Representation:
Group means, standard deviations, upper limits of normal
Age Groups:
Men 18-30 y.o., 31-50 y.o., ≥51 y.o.